What we are researching
The purpose of this study is to learn how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach, in people using one of three GLP-1 medications.
Who may participate
Each clinical trial has its own requirements for who can participate, often called eligibility criteria. Some of the key criteria for this study are listed here. Discuss these requirements with your study doctor to determine if you may be eligible to participate. Additional criteria for your doctor to review can be found here NCT07225816.
Overweight or Obesity
Have a body mass index (BMI) from 25 to 45
Type 2 Diabetes (T2D)
You are eligible with or without T2D, but if you have T2D, you must meet the following criteria:
Have been diagnosed with T2D, more than 180 days (about 6 months) before screening for the study
Either no treatment with antidiabetic medicine or a stable dose of metformin for at least 90 days before screening for the study
Age
18+ years
Study Medicine
Either a once daily tablet by mouth, once daily injection, or once weekly injection, depending on your study group
Number of study visits
Up to 14 visits over a period up to 7 months
There may be fewer visits over a shorter period, based on your study group
What to expect
If your study doctor determines that you are eligible and you decide to participate, you will be enrolled into the study.
Once enrolled, you will be placed into one of two groups. Both groups will receive active study medicine. For study medicine given by injection, the injection will be given under the skin, using an injection pen. Your study team will teach you how to use the injection pen.
Your participation is expected to last about 7 months and will involve five overnight stays (ranging from 2 to 10 nights, depending on your study group). Visits may include physical exams, lab tests and questionnaires to monitor your health and safety.
Call 866-867-7178 or email clinicaltrials@novonordisk.com to learn more
about the study and find out whether there is a participating study site near you.
When you call, please reference study 8438
You may also choose to discuss this clinical trial with your healthcare provider.